LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.48 -1.33

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.48

Max

1.6099999999999999

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+166.89% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	137M 631M
Eelmine avamishind	2.81
Eelmine sulgemishind	1.48

Uudiste sentiment

By Acuity

50%

161 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. veebr 2026, 23:07 UTC

Tulu

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24. veebr 2026, 23:01 UTC

Tulu

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24. veebr 2026, 22:59 UTC

Tulu

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24. veebr 2026, 22:42 UTC

Tulu

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24. veebr 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24. veebr 2026, 23:46 UTC

Market Talk

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24. veebr 2026, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24. veebr 2026, 23:30 UTC

Market Talk

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24. veebr 2026, 23:20 UTC

Market Talk

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24. veebr 2026, 23:20 UTC

Market Talk

Global Equities Roundup: Market Talk

24. veebr 2026, 23:16 UTC

Tulu

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24. veebr 2026, 23:13 UTC

Tulu

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24. veebr 2026, 23:12 UTC

Tulu

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24. veebr 2026, 23:10 UTC

Tulu

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24. veebr 2026, 23:10 UTC

Tulu

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24. veebr 2026, 23:08 UTC

Tulu

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24. veebr 2026, 23:07 UTC

Tulu

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24. veebr 2026, 22:52 UTC

Tulu

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24. veebr 2026, 22:46 UTC

Tulu

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24. veebr 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Warner Receives New Bid From Paramount -- 3rd Update

24. veebr 2026, 22:29 UTC

Tulu

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24. veebr 2026, 22:28 UTC

Tulu

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24. veebr 2026, 22:27 UTC

Tulu

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24. veebr 2026, 22:27 UTC

Tulu

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24. veebr 2026, 22:25 UTC

Tulu

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24. veebr 2026, 22:24 UTC

Tulu

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24. veebr 2026, 22:23 UTC

Tulu

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24. veebr 2026, 22:22 UTC

Tulu

Woolworths Interim Dividend 45 Australian Cents/Share

24. veebr 2026, 22:22 UTC

Tulu

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24. veebr 2026, 22:21 UTC

Tulu

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

166.89% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 166.89%

Kõrge 6 USD

Madal 2.1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

161 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.